Real World Healthcare Resources Utilization Associated with the Management of Patients with Relapsed or Refractory Multiple Myeloma in Spain: The Charismma Study
Author(s)
Rosiñol L1, Grande M2, Fernández A2, Coutinho H3, Ocio EM4
1Hospital Clinic, Barcelona, Spain, 2Takeda Farmaceutica España, Madrid, Spain, 3Takeda Farmacéutica España, Madrid, Spain, 4Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain
OBJECTIVES To describe the healthcare resource utilization of real-world patients with relapsed or refractory multiple myeloma (RRMM) under active treatment. METHODS Multicenter, cross-sectional study of patients routinely treated in Spain between 2017 and 2018. Data were retrieved from either the clinical records or a structured interview. RESULTS The study included 276 patients with RRMM (mean age 67.4 years; SD 10.5), enrolled with a median of 1.61 months (Q1-Q3 0.74-3.14) after the last relapse. At enrollment, 119 (43.3%), 71 (25.8%), and 85 (30.9%) patients initiated second-line, third-line, and ≥fourth-line therapy, respectively; 12 patients underwent stem cell transplant. Most patients were retired (n=179; 65.1%) and lived in urban areas (n=209; 75.7%) with their relatives (n=235; 85.8%); 79 (28.7%) patients had some degree of dependence. Patients lived 0.5-to-530 Km away from the healthcare center (median 9.0; Q1-Q3 3-30); 183 patients (67.8%) traveled to the hospital in their private vehicle. Last relapse management required a mean of 4.1 trips every month (SD 4.8) to the healthcare center, with a monthly cost ranging from 0 to 1,160€ (median 15.8; Q1-Q3 5.0-42.0). Along this relapse, 60/155 (38.7%) required to attend the emergency department, and 92/155 (59.4%) were admitted to the hospital (mean length of stay 16 days); 270 patients (97.8%) visited the hematologist, a median of 4 times (Q1-Q3 2-6). Median (Q1-Q3) number of visits alone and with a caregiver were 2 (2-4) and 4 (2-6), respectively; 112 caregivers (54.4%) were employed. Aside from the specialist, 60 patients (21.7%) visited their GP, a median of 1 time (1-2.5) alone and 2 (1-4) accompanied; 227 patients (82.2%) required an imaging exam: 43.2% x-ray, 29.5% computerized tomography, and 20.7% magnetic resonance. CONCLUSIONS RRMM is associated with a significant societal burden and healthcare resources utilization, which affects patients and caregivers. These factors should be considered when prescribing treatments for RRMM.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PCN342
Topic
Clinical Outcomes, Economic Evaluation, Health Service Delivery & Process of Care
Topic Subcategory
Clinician Reported Outcomes, Disease Management, Hospital and Clinical Practices, Work & Home Productivity - Indirect Costs
Disease
Oncology